Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patie… Read more
Actinium Pharmaceuticals Inc (ATNM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.459x
Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has a cash flow conversion efficiency ratio of -0.459x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.33 Million) by net assets ($13.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Actinium Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Actinium Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Actinium Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mermaid Maritime Public Company Limited
PINK:MMMPF
|
-0.015x |
|
Gulshan Polyols Limited
NSE:GULPOLY
|
-0.040x |
|
Advice It Infinite Pcl
BK:ADVICE
|
0.024x |
|
King Gen PCL
BK:KGEN
|
0.024x |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
0.023x |
|
Madison County Financial Inc
PINK:MCBK
|
0.004x |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
-0.314x |
|
Harmony Electronics
TWO:8182
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Actinium Pharmaceuticals Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.76 Million | $-33.07 Million | -1.010x | +22.41% |
| 2023-12-31 | $36.38 Million | $-47.34 Million | -1.301x | -1100.72% |
| 2022-12-31 | $66.48 Million | $8.64 Million | 0.130x | +145.83% |
| 2021-12-31 | $73.55 Million | $-20.87 Million | -0.284x | +19.52% |
| 2020-12-31 | $61.32 Million | $-21.62 Million | -0.353x | +90.73% |
| 2019-12-31 | $5.64 Million | $-21.46 Million | -3.802x | -62.89% |
| 2018-12-31 | $8.81 Million | $-20.57 Million | -2.334x | -48.06% |
| 2017-12-31 | $13.67 Million | $-21.55 Million | -1.577x | -36.57% |
| 2016-12-31 | $18.01 Million | $-20.79 Million | -1.154x | -36.80% |
| 2015-12-31 | $21.97 Million | $-18.54 Million | -0.844x | -111.31% |
| 2014-12-31 | $-1.92 Million | $-14.35 Million | 7.463x | +84.98% |
| 2013-12-31 | $-1.56 Million | $-6.29 Million | 4.035x | +188.68% |
| 2012-12-31 | $1.15 Million | $-5.21 Million | -4.550x | -71087.78% |
| 2011-12-31 | $-84.33K | $539.00 | -0.006x | +92.28% |
| 2010-12-31 | $-94.62K | $7.83K | -0.083x | -142.45% |
| 2009-12-31 | $-96.29K | $-18.78K | 0.195x | +3.32% |
| 2008-12-31 | $-73.96K | $-13.96K | 0.189x | -59.53% |
| 2007-12-31 | $-33.20K | $-15.49K | 0.467x | -38.81% |
| 2006-12-31 | $-18.40K | $-14.03K | 0.763x | -- |